Biohaven's Phase 2 trial of its muscle-building product taldefgrobep alfa will read out later this year, with Eli Lilly’s similar muscle-boosting drug in its sights.
July 8, 2026 10:26 AM EDT
Biohaven looks to take on Lilly in the muscle-sparing obesity space
Elizabeth Cairns
Senior biopharma journalist
They say that the way to make money in a gold rush is to open a shop selling picks and shovels. By the same token …
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and…
Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the effectiveness…
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other…
It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured…
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight…
